Skip to Main Content
11/16/2026|7 minute read

Key Takeaways

  • The Department of Justice (DOJ or Department) and the Department of Health and Human Services Office of Inspector General (HHS-OIG) have announced a new policy and new program, both designed to incentivize companies to self-disclose potential violations of federal healthcare laws.
  • As the Department recognized, in the healthcare context, a single course of conduct frequently gives rise to overlapping criminal, civil and administrative matters, complicating the decision of whether and where to self-report. On Oct. 15, Assistant Attorney General (AAG) Colin M. McDonald, DOJ National Fraud Enforcement Division (Fraud Division or Division), announced a new policy that streamlines the process for companies to voluntarily self-report potential healthcare-related criminal conduct and secure distinct disclosure benefits from both DOJ and HHS-OIG (the Policy). Now, companies that voluntarily disclose such conduct to the Fraud Division will not only receive the benefit of DOJ’s criminal Corporate Enforcement Policy (CEP), but “shall” also qualify for HHS-OIG’s Self-Disclosure Protocol (SDP) covering civil monetary penalties so long as the disclosure satisfies the CEP’s requirements.
  • The SDP will now apply without a separate report to HHS-OIG. But to benefit from both policies, companies must self-disclose potentially criminal conduct to the Fraud Division – corporate self-disclosures made only to HHS-OIG will not generally qualify as “voluntary disclosure” under the CEP.
  • Further, on Oct. 22, DOJ’s Civil Division, HHS-OIG and the Centers for Medicare & Medicaid Services (CMS) announced a six-month Healthcare False Claims Act (FCA) Self-Disclosure Pilot Program (Pilot Program). They did so shortly after DOJ announced a separate, broader fast-track whistleblower rewards program in the criminal context. Under the civil Pilot Program, companies that disclose FCA violations will receive multiple benefits, including a coordinated civil liability release, no factual admissions, no Corporate Integrity Agreement and a favorable financial resolution with a set range for the repayment multiplier.
  • The Policy and the Pilot Program reflect enhanced benefits to companies that self-disclose potential criminally fraudulent conduct and FCA violations involving healthcare, and they provide clear paths to make such reports. But in practice, the onus remains on companies to investigate internal misconduct thoroughly and determine whether conduct is potentially criminal, civil or both. Prudent companies will consider engaging outside counsel quickly to conduct prompt and thorough investigations into potential misconduct and to analyze whether and to whom they should disclose misconduct to ensure they can reap the benefits of DOJ’s criminal CEP, HHS-OIG’s civil SDP and the new Pilot Program.

Key Details

Earlier this year, DOJ created a new Fraud Division and tasked it to “zealously investigate and prosecute those who steal or fraudulently misuse taxpayer dollars.”[1] On Oct. 1, AAG McDonald issued a memorandum to the Fraud Division that provided additional guidance on the Division’s investigation and prosecution of corporate entities.[2] On Oct. 7, AAG McDonald released another memorandum that directed the Fraud Division to prioritize prosecuting healthcare fraud schemes, among others.[3] The Policy and the Pilot Program build on these prior directives, and both use self-disclosure as a means of combating healthcare fraud and other violations of law.

Fraud Division and HHS-OIG Policy

The Policy recognizes that in “the health care fraud context, a single course of conduct – e.g., an illegal remuneration arrangement, a scheme to bill for medically unnecessary services, or a scheme involving an excluded person – frequently gives rise to overlapping criminal, civil, and administrative matters involving the Health Care Fraud Section” and HHS-OIG.[4] Accordingly, a single course of conduct may result in multiple, different consequences, complicating the decisions of a company that uncovers potentially criminal conduct about not only whether to self-report it, but also to whom.[5] Emphasizing a desire to avoid delay and the potential that evidence could become stale, the Policy clarifies that companies should disclose to the Fraud Division potentially criminal conduct involving “federal health care program funds, patients, consumers, and investors.”[6]

Under the Policy, a company need only make one disclosure – to the Health Care Fraud Section (or another DOJ component) – to obtain the benefits of voluntary self-disclosure under both DOJ’s CEP, which applies to criminal matters, and HHS-OIG’s SDP, which applies to civil matters.[7] The disclosure must satisfy the CEP’s requirements.[8] Accordingly, “[a] party in the health care industry that seeks to benefit from both” the CEP and the SDP “should make its initial disclosure of potentially criminal conduct to the Fraud Division,”[9] because a disclosure to HHS-OIG “generally does not qualify as a voluntary self-disclosure to the Fraud Division” under the CEP.[10] The Policy qualifies this directive, however, by noting that prosecutors retain the discretion to recommend a declination based on the severity of the circumstances and other factors, and that prosecutors may consider disclosures to either government entity as part of a company’s cooperation and remediation.[11]

DOJ’s Civil Division and HSS-OIG Pilot Program

The Pilot Program notes that DOJ and HHS have “long encouraged the healthcare industry to proactively invest in compliance and transparently engage with the government.”[12] Accordingly, the Pilot Program seeks to build on these “long-standing efforts to incentivize disclosure”[13] in the healthcare space by “offer[ing] a clear and predictable pathway for companies seeking to obtain a coordinated resolution of civil liability” under the FCA and several HHS administrative authorities.[14] The Pilot Program is designed to “support[] legitimate American healthcare businesses endeavoring to quickly and cooperatively resolve prior misconduct and move forward with a clean slate.”[15] The announcement distinguishes those entities from “illegitimate businesses that knowingly exploit the generosity of the American people through various fraudulent schemes.”[16]

The following entities are eligible to participate in the Pilot Program: “[h]ealthcare providers, suppliers, manufacturers, payors, and related entities that furnish, arrange for, manufacture, distribute, insure, administer, or bill for items or services reimbursed, subsidized or otherwise paid for, directly or indirectly, by HHS Federal health care programs.”[17] To be eligible for a resolution under the Pilot Program, the self-disclosure must identify a potential violation of the FCA of which the government was not previously aware.[18] Disclosures must be received on or before April 22, 2027.[19]

The announcement outlines several components required for a disclosure to be considered. It must:

(1) “Describe all relevant details relating to the disclosing company’s conduct that, in the disclosing company’s reasonable assessment, potentially violate the FCA … including the specific laws, regulations, or other binding requirements that were violated and the time period of the violations.”

(2) “Append as exhibits all documents sufficient to fully reflect the nature, terms, and operation of the disclosed FCA violations.”

(3) “Specify the remedial measures or other corrective action the disclosing company has taken to terminate the disclosed potential FCA violations and prevent them from reoccurring.”

(4) “Provide financial information sufficient to facilitate the DOJ Civil Division calculating the Base Self-Disclosure Repayment.”

(5) “Include a certification from the disclosing company’s authorized representative stating that to the best of the individual’s knowledge, the submission contains truthful and complete information about the disclosed potential FCA violations.”

(6) Include contact information for the company’s designated point of contact for any follow-up questions.[20]

Self-disclosing companies receive numerous benefits under the Pilot Program. Specifically, companies will “receive favorable treatment from DOJ Civil Division and HHS in a coordinated civil release, with no factual admissions.”[21] Further, DOJ will provide self-disclosing companies with a release under the FCA, and HHS-OIG will not require a Corporate Integrity Agreement as part of a Pilot Program resolution. Further, CMS will not impose civil monetary penalties or seek revocation. Companies will also receive “favorable financial resolutions,” with repayments calculated using a fixed multiplier of 1.25 to 1.60 times the Base Self-Disclosure Repayment.[22] The exact multiplier will be determined by evaluating the timeliness of the company’s disclosure, the duration and scope of misconduct, the involvement of senior leadership, the financial benefit to the disclosing company, and whether the disclosing company has successor liability for conduct that it promptly remediated.[23]

Practical Considerations for Companies and Executives

The Policy and the Pilot Program build on DOJ’s prior guidance that emphasizes the Department’s interest in voluntary self-disclosure as an important component of combating fraud.[24] Both the Policy and the Pilot Program incentivize companies to disclose potential healthcare fraud or other violations of law in the healthcare space by providing them with significant benefits for self-reporting. The Department has telegraphed a significant future uptick in fraud investigations and prosecutions, particularly in the healthcare context. Companies in the healthcare industry should consider the Policy, the Pilot Program and DOJ’s prior guidance in their risk assessments and should review their policies and procedures to ensure current compliance with the law.[25] Companies should also ensure that they are able to react quickly upon learning of potential misconduct because credit for self-disclosure under the CEP and the Pilot Program hinges in part on the government not previously being aware of the potential violations of law. It is prudent for companies to engage outside counsel, conduct a thorough investigation and work with counsel to determine whether and to whom self-disclosure is appropriate, and to evaluate whether the misconduct might be criminal, civil or both.

The BakerHostetler White Collar, Investigations and Securities Enforcement and Litigation and the Criminal Tax Defense teams are composed of dozens of experienced individuals, including numerous attorneys who have served in DOJ and at the SEC. Our attorneys include four former U.S. attorneys, several former assistant U.S. attorneys and unit chiefs, attorneys who served in DOJ’s Tax Division, and attorneys who served in the SEC’s Division of Enforcement. Our teams have extensive experience in defending regulatory investigations and litigation, conducting enterprise-wide, business-line and regulatory area-specific risk assessments, providing compliance counseling, and assisting companies with navigating successful self-reports to the government.

Please feel free to contact any of our experienced professionals if you have questions about this alert.


[1] Memorandum from Acting Att’y Gen. Todd Blanche, Creation of the National Fraud Enforcement Division (Apr. 7, 2026), available at https://www.justice.gov/ag/media/1435311/dl?inline.

[2] Memorandum from Assistant Att’y Gen. Colin M. McDonald, Directive 26-12: Corporate Enforcement in the Fight Against Fraud (Oct. 1, 2026), available at https://www.justice.gov/opa/media/1463571/dl?inline; see also U.S. Dep’t of Justice, Justice Manual §§ 9.28-000 et seq. (2026).

[3] Memorandum from Assistant Att’y Gen. Colin M. McDonald, Directive 26-13: A Comprehensive Approach in the Fight Against Fraud (Oct. 7, 2026), available at https://www.justice.gov/opa/media/1465036/dl?inline.

[4] Policy announcement from Assistant Att’y Gen. Colin M. McDonald, “National Fraud Enforcement Division & HHS-OIG Policy on Coordination of Voluntary Self-Disclosure in Health Care Fraud Matters”(Oct. 15, 2026), available at https://www.justice.gov/opa/media/1466291/dl?inline.

[5] See id.

[6] Id.

[7] Id.

[8] Id.

[9] Id.

[10] Id.

[11] Id.

[12] Dep’t of Justice and Dep’t of Health & Human Services Healthcare Self-Disclosure Pilot Program(Oct. 22, 2026), available at https://www.justice.gov/opa/media/1467546/dl.

[13] Id.

[14] Id.

[15] Id.

[16] Id.

[17] Id.

[18] See id.

[19] See id.

[20] Id.

[21] Id.

[22] See id.

[23] See id.

[24] Id.

[25] Importantly, notwithstanding DOJ’s current priorities, statutes of limitations for employee misconduct frequently extend beyond a single administration’s term. Companies should continue to be diligent about compliance in all areas and forms.


Featured Insights